title: Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.
abstract: Spironolactone and eplerenone are widely used as mineralocorticoid antagonists. Spironolactone has several nonspecific actions including inhibition of androgen receptor and steroid hormone biosynthesis. While studies have shown that eplerenone does not exhibit nonspecific actions on androgen receptor, its effects on steroid hormone production have not been reported. Herein, the effects of eplerenone (0.1-30 microM) and spironolactone (0.1-30 microM) on steroid production were examined in human adrenocortical H295R cells. Spironolactone inhibited basal production of cortisol (91%) and aldosterone (53%). Treatment of H295R cells with angiotensin II (Ang II) for 24 h increased aldosterone production by 11-fold. Spironolactone inhibited Ang II stimulation of aldosterone production by 80%. Addition of pregnenolone increased aldosterone (9-fold) and cortisol (3-fold) production. Spironolactone inhibited pregnenolone metabolism to aldosterone (67%) and cortisol (74%). The inhibitory effects of spironolactone occurred at concentrations far higher than those needed to block mineralocorticoid receptor, suggesting an action directly on the enzymes involved in steroid production. In contrast, eplerenone did not inhibit basal, Ang II, forskolin, pregnenolone-stimulated cortisol, or aldosterone production. Together, these data demonstrate that opposed to spironolactone, pharmacologic concentrations of eplerenone do not inhibit adrenal cell aldosterone or cortisol production.
authors.affiliation: Department of Physiology, Medical College of Georgia, Augusta, GA 30912, USA.
authors.forename: P
authors.initials: P
authors.lastname: Ye
authors.forename: T
authors.initials: T
authors.lastname: Yamashita
authors.forename: D M
authors.initials: DM
authors.lastname: Pollock
authors.forename: H
authors.initials: H
authors.lastname: Sasano
authors.forename: W E
authors.initials: WE
authors.lastname: Rainey
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D000077545:Eplerenone; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D008901:Mineralocorticoids / Q000037:antagonists & inhibitors / Q000378:metabolism; D018161:Receptors, Mineralocorticoid / Q000378:metabolism / Q000502:physiology; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000494:pharmacology*; D013256:Steroids / Q000096:biosynthesis*; D015533:Transcriptional Activation / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D008901:Mineralocorticoids; D018161:Receptors, Mineralocorticoid; D013256:Steroids; D013148:Spironolactone; D000077545:Eplerenone; D006854:Hydrocortisone